» Articles » PMID: 36233487

Non-Tuberculous Mycobacteria and Lung Co-Infection: Systematic Review

Overview
Journal J Clin Med
Specialty General Medicine
Date 2022 Oct 14
PMID 36233487
Authors
Affiliations
Soon will be listed here.
Abstract

Non-tuberculous mycobacteria (NTM) and pulmonary co-infection occurs in patients with underlying lung disease and is rarely reported. We conducted a systematic search of NTM and pulmonary co-infection in PubMed, EMBASE, and Cochrane Library to identify cases published from 1977 to May 2022. We included 507 articles comprising 1538 cases (only 817 patients with partial relevant clinical data). Of these, 54.3% of patients were men, with a mean age of 57.7 years. Chronic obstructive pulmonary disease (21.1%), previous diagnosis of tuberculosis (18%), and asthma (11.1%) were the most common chronic lung diseases, and corticosteroids were used in 36.8% of patients. The most frequent symptoms were cough (68.2%), dyspnea (59.1%), and hemoptysis (34.1%). The most common radiological findings were bronchiectasis (52.3%) and cavitation (40.8%). NTM and were treated simultaneously in 47.3% of cases, whereas NTM-targeted therapy only was performed in 23.4% and only in 1.6%. The remaining 27.7% did not receive any treatment and were considered to be colonized. The global mortality rate was 43% (159/370). There was an increased prevalence of NTM and pulmonary aspergillosis among patients with underlying chronic lung diseases, which led to severe pulmonary affection with a poor global prognosis.

Citing Articles

Identification of prognostic factors of chronic pulmonary aspergillosis: a retrospective cohort of 106 patients.

Zhu Z, Hao H, Tao R, Zhang Y J Thorac Dis. 2024; 16(11):7310-7319.

PMID: 39678851 PMC: 11635279. DOI: 10.21037/jtd-24-831.


The Association of Chronic Pulmonary Aspergillosis and Chronic Pulmonary Histoplasmosis with MDR-TB Patients in Indonesia.

Soeroso N, Siahaan L, Khairunnisa S, Anggriani R, Aida A, Eyanoer P J Fungi (Basel). 2024; 10(8).

PMID: 39194855 PMC: 11355089. DOI: 10.3390/jof10080529.


Treatable traits and challenges in the clinical management of non-tuberculous mycobacteria lung disease in people with cystic fibrosis.

Gramegna A, Misuraca S, Lombardi A, Premuda C, Barone I, Ori M Respir Res. 2023; 24(1):316.

PMID: 38104098 PMC: 10725605. DOI: 10.1186/s12931-023-02612-1.


Lady Windermere syndrome with haemoptysis: suspected pulmonary aspergilloma and MAC pulmonary disease.

Nazarenko N, Borkowski P, Berges M, Varrias D BMJ Case Rep. 2023; 16(9).

PMID: 37714562 PMC: 10510905. DOI: 10.1136/bcr-2023-256349.

References
1.
Wickremasinghe M, Ozerovitch L, Davies G, Wodehouse T, Chadwick M, Abdallah S . Non-tuberculous mycobacteria in patients with bronchiectasis. Thorax. 2005; 60(12):1045-51. PMC: 1747265. DOI: 10.1136/thx.2005.046631. View

2.
Ng T, Robson G, Denning D . Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology (Reading). 1994; 140 ( Pt 9):2475-9. DOI: 10.1099/13500872-140-9-2475. View

3.
Godet C, Philippe B, Laurent F, Cadranel J . Chronic pulmonary aspergillosis: an update on diagnosis and treatment. Respiration. 2014; 88(2):162-74. DOI: 10.1159/000362674. View

4.
Drayton J, Dickinson G, Rinaldi M . Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin Infect Dis. 1994; 18(2):266. DOI: 10.1093/clinids/18.2.266. View

5.
Takeda K, Imamura Y, Takazono T, Yoshida M, Ide S, Hirano K . The risk factors for developing of chronic pulmonary aspergillosis in nontuberculous mycobacteria patients and clinical characteristics and outcomes in chronic pulmonary aspergillosis patients coinfected with nontuberculous mycobacteria. Med Mycol. 2015; 54(2):120-7. DOI: 10.1093/mmy/myv093. View